Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bayer AGXSWX:BAYN 51 3-Year FCF Growth Rate is -6.00% as of Jun. 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 51/100 and a GF Value™ of CHF24.57 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 659 Drug Manufacturers companies, Bayer AG ranks worse than 65.71% on this metric.
During the past 12 months, Bayer AG's average Free Cash Flow per Share Growth Rate was -54.80% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -6.00% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 8.70% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was -7.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Bayer AG was 104.60% per year. The lowest was -27.10% per year. And the median was 2.30% per year.
Bayer AG (XSWX:BAYN) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Bayer AG 3-Year FCF Growth Rate Related Terms
XSWX:BAYN vs LLY, JNJ, ABBV: 3-Year FCF Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG 3-Year FCF Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Bayer AG's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of -6.00% mean?
Bayer AG (XSWX:BAYN) has a 3-Year FCF Growth Rate of -6.00% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Bayer AG and its competitors. According to the industry distribution chart, Bayer AG ranks #433 out of 659 companies in the Drug Manufacturers industry, placing it in the top 65.7%.
Is Bayer AG's 3-Year FCF Growth Rate too high?
Bayer AG's current 3-Year FCF Growth Rate is -6.00%. Based on the distribution chart, Bayer AG ranks #433 out of 659 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bayer AG has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's 3-Year FCF Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #433 out of 659 companies for 3-Year FCF Growth Rate. This places Bayer AG in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 8.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Drug Manufacturers company?
The median 3-Year FCF Growth Rate among Drug Manufacturers companies is 8.90, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Bayer AG and its competitors. For the Drug Manufacturers industry, the median 3-Year FCF Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current 3-Year FCF Growth Rate is -6.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.57, compared to a current price of CHF45.57 — trading 85.5% above its estimated fair value. The current 3-Year FCF Growth Rate is -6.00%. Bayer AG's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current 3-Year FCF Growth Rate is -6.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF45.57 is trading 85.5% above its estimated GF Value™ of CHF24.57.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
3-Year FCF Growth Rate: -6.00%
GF Value™: CHF24.57 vs. price of CHF45.57 (85.5% above fair value)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
51GF Score
Get the complete analysis for XSWX:BAYN
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
